MedImmune absorbed into AZ mothership as Cambridge expansion continues
MedImmune’s corporate brand is being retired as biologics are integrated into AstraZeneca’s two new research and development units.
AstraZeneca, which is building major corporate and research facilities at the Cambridge Medical Campus, had flagged up organisational changes in January to support continued scientific innovation and commercial success as the company enters a new phase in its strategic development.
This includes the creation of therapy area-focused Research & Development units that are responsible for discovery through to late-stage development - one for BioPharmaceuticals (cardiovascular, renal & metabolism and respiratory) and one for oncology.
While the MedImmune name and logo will disappear, a proud legacy of scientific innovation remains, as does the entrepreneurial culture that MedImmune has stood for over its 30-year history.
Today nearly half of the AstraZeneca pipeline is comprised of biologics, providing momentum for the company’s newly structured R & D units to continue to discover and develop life-changing treatments as a fully integrated organisation.
External collaborations and partnerships held by MedImmune will continue. The MedImmune website will be redirected to AstraZeneca.com and MedImmune social media properties will be discontinued.
AstraZeneca social media properties will continue to carry news and updates about biologic pipeline advancements and scientific innovations. MedImmune communities and stakeholders can continue to expect to receive the same level of scientific updates on those channels.
In addition, recruiting channels will remain active and visible via AstraZeneca to ensure prospective talent remains aware of opportunities.
AstraZeneca is not currently making announcements about any changes to management and headcount at MedImmune in Cambridge where the brilliant Jane Osbourn heads up operations but Business Weekly expects developments on this front in due course.
MedImmune made its Cambridge bow almost 13 years ago when CAT was acquired by AstraZeneca for £702 million in 2006. AstraZeneca subsequently acquired MedImmune which it combined with CAT to form a global biologics division under the MedImmune brand.